EN DE
Watch Telemedycyna Polska S.A for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Telemedycyna Polska S.A (TMP) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Telemedycyna Polska S.A stock PLN 0.28, price PLN 0.40, that is 29.7% below the price, quality 38 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare PL · ISIN PLTLMDC00018

TP Telemedycyna Polska S.A logo Thin data Nov 10, 2026

Telemedycyna Polska S.A

TMP · WAR
Expensive, weak quality

Our calculation puts a fair price 30% below what the stock costs today.

Negative equity (buybacks among others)
Fair value 0.2813 PLN · Overvalued
Quality 38/100
Weak Growth (revenue 3y −6.4 %/yr in PLN)
Loss-making · -17.8% net margin (TTM)
Negative free cash flow
Trails peers (2/7)
Narrow moat 16/100
Thin data
Estimate⚠ Thinly traded
Watch Telemedycyna Polska S.A for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

1.95 PLN 0.3400 PLN Fair Value 0.2813 PLN Oct 2020 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 0.3400 PLN – 1.95 PLN · fair‑value band 0.2110 PLN – 0.3516 PLN · the 0.4000 PLN price screens above the 0.2813 PLN fair value. As of Nov 10, 2026.

Follow Telemedycyna Polska in your weekly email

Every Wednesday you see whether Telemedycyna Polska is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Telemedycyna Polska S.A. provides medical and telemedicine services in Poland.

Show moreShow less

The company offers remote monitoring, such as Cardiology telemonitoring, Telecare for seniors, and remote medical emergency center; telemedicine services in the field of cardiology diagnostics and care for primary health care facilities, hospitals and social welfare homes, cardiology, sports medicine, and occupational medicine offices.

It also provides wellbeing programs and health, medical events, preventive, and educational campaigns, as well as support for the pharmaceutical industry and target group research. Telemedycyna Polska S.A. was founded in 2005 and is headquartered in Katowice, Poland.

Stock analysis

Telemedycyna Polska S.A (TMP) currently trades at 0.4000 PLN, while our estimate is 0.2813 PLN, 30% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 0.2110 PLN (bear) to 0.3516 PLN (bull), the price of 0.4000 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Telemedycyna Polska S.A reported revenue of 5.3M PLN in FY2025 versus 6.5M PLN in FY2022, a compound −6.4%/yr. Reported net income was −1.6M PLN in FY2025.

Key figures

Market cap 8.0M PLN (≈ $2.0M) Micro · P/S ratio 1.44 · EPS (TTM) −0.0700 PLN · Net margin −30.5% · Return on assets (EBIT) −53.5% (4-year average) · Operating margin −8.2% · Revenue (TTM) 5.5M PLN · Revenue growth (YoY) +10.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 49% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −35% fair-value upside, at −30%, TMP screens cheaper than that median.

Fair Value

Bear 0.2110 PLN Fair Value 0.2813 PLN Bull 0.3516 PLN
Price 0.4000 PLN · Downside -29.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 40
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 8
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 1
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 7
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−2.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−17.5% (2022) → −26.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

TMP screens overvalued: fair value 30% below the price. Compare with Veeva Systems Inc →

Compare Telemedycyna Polska S.A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 141 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside −29.7% · Below median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −90.4% · Bottom 25%
Net margin (12 months) −17.8% · Below median
Operating margin (12 months) −8.2% · Below median
Growth and dividend
Revenue growth (quarter YoY) 10.5% · Above median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 1.45× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 13
FUTURE (revenue growth)53 · sector 45
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 46

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Doximity, Inc DOCS $32.42 $36.16 +12% vs TMP
Veeva Systems Inc VEEV $305.55 $337.04 +10% vs TMP
HealthEquity, Inc HQY $103.54 $112.32 +8% vs TMP
Waystar Holding WAY $29.30 $29.10 −1% vs TMP
Tempus AI, Inc TEM $80.54 $52.58 −35% vs TMP
HeartFlow, Inc HTFL $55.80 $34.82 −38% vs TMP
Hinge Health, Inc HNGE $123.23 $51.25 −58% vs TMP
Pro Medicus Limited PME A$207.31 A$85.12 −59% vs TMP
BrightSpring Health Services, Inc BTSG $72.49 $25.72 −65% vs TMP
XtalPi Holdings 2228 HK$6.37 HK$1.53 −76% vs TMP

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Telemedycyna Polska S.A: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Telemedycyna Polska S.A Fair Value". https://www.fairvalue-calculator.com/stock/TMP.WAR

Frequently asked questions

Is Telemedycyna Polska S.A (TMP) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 0.2813 PLN versus a price of 0.4000 PLN, about 30% lower (overvalued).
What is the fair value of TMP?
Our estimate for Telemedycyna Polska S.A is 0.2813 PLN (as of Nov 10, 2026), built from audited fundamentals. The current price: 0.4000 PLN.
What is the quality score of TMP?
Telemedycyna Polska S.A has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Telemedycyna Polska S.A (TMP)?
Our calculated price target is the estimate of 0.2813 PLN (as of Nov 10, 2026). Cautious scenario 0.2110 PLN, optimistic scenario 0.3516 PLN. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Telemedycyna Polska S.A stock forecast for 2026?
Our estimate puts fair value at 0.2813 PLN, about 30% lower versus a price of 0.4000 PLN (overvalued). Cautious scenario 0.2110 PLN, optimistic scenario 0.3516 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Telemedycyna Polska S.A (TMP)?
Telemedycyna Polska S.A reported trailing-twelve-month revenue of about 5.5M PLN (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Telemedycyna Polska S.A (TMP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Telemedycyna Polska S.A it is 0.2813 PLN per share (as of Nov 10, 2026), against a price of 0.4000 PLN.
Is Telemedycyna Polska S.A stock overvalued or undervalued in 2026?
As of Nov 10, 2026, TMP trades above its calculated fair value: price 0.4000 PLN, fair value 0.2813 PLN, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TMP?
No. The price is what the market pays today (0.4000 PLN); the fair value is what the company's own numbers justify (0.2813 PLN). For Telemedycyna Polska S.A the two are 0.1187 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Telemedycyna Polska S.A worth?
The market values Telemedycyna Polska S.A at about 8.0M PLN (market capitalisation, as of Nov 10, 2026). Per share that is 0.4000 PLN; our models calculate a fair value of 0.2813 PLN per share.
What do the bullish and bearish scenarios say about TMP?
Our models span a range for Telemedycyna Polska S.A: cautious scenario 0.2110 PLN, base 0.2813 PLN, optimistic 0.3516 PLN per share (as of Nov 10, 2026, price 0.4000 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Telemedycyna Polska S.A (TMP)?
Balance-sheet figures for Telemedycyna Polska S.A (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is TMP from its 52-week high?
Telemedycyna Polska S.A trades at 0.4000 PLN, about 49% below its 52-week high of 0.7850 PLN and 18% above the low of 0.3400 PLN (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 0.2813 PLN is for.
Which stocks are comparable to Telemedycyna Polska S.A?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Tempus AI, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Telemedycyna Polska S.A stock attractive at the current price?
The data as of Nov 10, 2026: price 0.4000 PLN, calculated fair value 0.2813 PLN (−30%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Telemedycyna Polska S.A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Telemedycyna Polska S.A (TMP)?
The closing price on Nov 9, 2026 was 0.4000 PLN. Our estimate is 0.2813 PLN, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Telemedycyna Polska S.A right now?
The price sits above even our optimistic bull case (0.3516 PLN). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Telemedycyna Polska S.A

How large is the market capitalisation of Telemedycyna Polska S.A (TMP)?
The market capitalisation of Telemedycyna Polska S.A is 8.0M PLN (≈ $2.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Telemedycyna Polska S.A (TMP)?
The price-to-sales ratio of Telemedycyna Polska S.A is 1.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Telemedycyna Polska S.A (TMP)?
Earnings per share at Telemedycyna Polska S.A are −0.0700 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Telemedycyna Polska S.A (TMP)?
The net margin of Telemedycyna Polska S.A is −30.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Telemedycyna Polska S.A (TMP)?
On an EBIT basis the return on assets of Telemedycyna Polska S.A is −53.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Telemedycyna Polska S.A (TMP)?
The operating margin of Telemedycyna Polska S.A is −8.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Telemedycyna Polska S.A (TMP)?
Revenue at Telemedycyna Polska S.A is growing +10.5% versus a year earlier (3y avg −6.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Telemedycyna Polska S.A (TMP) generate?
The free cash flow of Telemedycyna Polska S.A is −1.1M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Telemedycyna Polska S.A in the live analysis

One click puts Telemedycyna Polska S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.